<DOC>
	<DOCNO>NCT01326962</DOCNO>
	<brief_summary>This open-label , single arm study evaluate safety efficacy RoActemra/Actemra ( tocilizumab ) patient active , moderate severe rheumatoid arthritis inadequate response disease-modifying antirheumatic drug ( DMARDs ) anti-TNF . Patients receive RoActemra/Actemra dose 8 mg/kg ( max 800 mg ) intravenously every 4 week total 6 infusion . Non-biologic DMARD therapy may continue throughout study . Anticipated time study treatment 24 week .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Patients With Rheumatoid Arthritis Who Have Inadequate Response DMARDs Anti-TNF</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Active moderate severe rheumatoid arthritis &gt; /= 6 month duration &gt; /=1 nonbiologic DMARD and/or antiTNF therapy stable dose &gt; /=8 week time prior study treatment Inadequate clinical response nonbiologic DMARD antiTNF therapy Oral corticosteroid must stable dose least 25 28 day prior first dose study drug Pregnant lactate woman Major surgery ( include joint surgery ) within 8 week prior screen major surgery plan within 6 month enrolment Rheumatic autoimmune disease RA Functional class IV ( ACR classification ) Prior history current joint disease RA Intraarticular parenteral corticosteroid within 6 week prior baseline Previous treatment RoActemra/Actemra Known active current history recurrent infection History currently active primary secondary immunodeficiency Active tuberculosis require treatment within previous 3 year Positive HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>